MedTrace Logo

EVI-01-IT Safety Study

NCT05422976 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-07-21

No results posted yet for this study

Summary

Prospective, single arm, pilot study to assess the safety and tolerability of a single intra-articular injection of EVI-01 for the treatment of symptomatic knee osteoarthritis.

Conditions

Interventions

DEVICE

EVI-01

High molecular weight Hyaluronic Acid

Sponsors & Collaborators

  • Donawa Lifescience

    collaborator UNKNOWN

  • Aptissen SA

    lead INDUSTRY

Principal Investigators

  • Stefano Zaffagnini, MD · IRCCS Istituto Ortopedico Rizzoli

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-23
Primary Completion
2023-05-31
Completion
2023-05-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05422976 on ClinicalTrials.gov